BioPontis Aims To Bridge "Valley Of Death"

BioPontis Alliance, a two-year old investment group, has been set up as a virtual network with the aim of introducing a new model for bridging the "valley of death" funding gap for early stage translational research. Its mission: to get more great science translated out of academia, say founders.

"Our mission is to get more great science translated out of academia," says Barbara Handelin, PhD, president of BioPontis Alliance LLC, a two-year old investment group set up as a virtual network with the aim of introducing a new model for bridging the "valley of death" funding gap for early stage translational research. "We think we have the right idea at the right time," Handelin claims. "There are piles of discoveries at universities" – 6,000 annual patent disclosures according to the Association of University Technology Managers. We want to test the robustness of that discovery science then translate that discovery into something that could become a product."

Translational research deals, especially the kind that bring together industry and academia, are a hot topic in biopharma circles these...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.